Sonoma Pharmaceuticals filings document the regulatory record for a Nasdaq-listed healthcare company with common stock trading under SNOA. Its disclosures include Securities Act registration statements, current reports on material events, proxy materials for shareholder voting matters, and common-stock and capital-structure information.
Recent filings cover material agreements involving Microcyn technology-based products, governance and executive or director changes, investor presentation materials, and proxy items related to corporate organization and stockholder approval mechanics. Registration statements and amendments describe offered securities, reporting-company status and related disclosure controls, while 8-K reports record definitive agreements, leadership matters and other company events affecting Sonoma’s operations and governance.